# CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

> **NCT06665087** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 110 (estimated)

## Conditions studied

- Colon Cancer
- Rectal Cancer

## Interventions

- **DRUG:** Ultrafractionated RT and CGA Guided systemic treatment.
- **RADIATION:** Ultrafractionated Radiotherapy
- **DRUG:** PD-1 antibody
- **DRUG:** Chemotherapy (Fluorouracil)
- **DRUG:** Chemotherapy (Raltitrexed)
- **DRUG:** Chemotherapy (Oxaliplatin)
- **DRUG:** Chemotherapy (CPT-11)
- **DRUG:** Targeted Therapy (anti-VEGF)
- **DRUG:** Targeted Therapy (anti-EGFR)

## Key facts

- **NCT ID:** NCT06665087
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11
- **Primary completion:** 2027-11
- **Final completion:** 2028-11
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06665087

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06665087, "CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06665087. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*